Doshi Dipal has filed 27 insider transactions across 2 companies since January 2024.
Most recent transaction: a grant/award of 139400 shares of Entrada Therapeutics, Inc. ($TRDA) on March 01, 2026.
Activity breakdown: 0 open-market purchases and 7 sales.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| March 1, 2026 | Entrada Therapeutics, Inc. | $TRDA | Doshi Dipal | CEO | A | Common Stock | 139400 | $0.00 | 555,064.0000 | 41,462,567 | 33.54% | 0.34% |
| March 1, 2026 | Entrada Therapeutics, Inc. | $TRDA | Doshi Dipal | CEO | A | Stock Option (Right to Buy) | 208000 | $0.00 | 208,000.0000 | 41,462,567 | 9999.99% | 0.50% |
| March 3, 2026 | Entrada Therapeutics, Inc. | $TRDA | Doshi Dipal | CEO | F | Common Stock | 19181 | $11.76 | 526,014.0000 | 41,462,567 | 3.52% | 0.05% |
| March 2, 2026 | Entrada Therapeutics, Inc. | $TRDA | Doshi Dipal | CEO | F | Common Stock | 9869 | $11.66 | 545,195.0000 | 41,462,567 | 1.78% | 0.02% |
| Feb. 5, 2026 | Azenta, Inc. | $AZTA | Doshi Dipal | Not found | A | Common | 5663 | $27.85 | 9,703.0000 | 45,929,000 | 140.17% | 0.01% |
| Sept. 2, 2025 | Entrada Therapeutics, Inc. | $TRDA | Doshi Dipal | CEO | F | Common Stock | 8723 | $5.43 | 415,664.0000 | 39,003,169 | 2.06% | 0.02% |
| March 1, 2025 | Entrada Therapeutics, Inc. | $TRDA | Doshi Dipal | CEO | A | Common Stock | 116200 | $0.00 | 441,953.0000 | 39,003,169 | 35.67% | 0.30% |
| March 3, 2025 | Entrada Therapeutics, Inc. | $TRDA | Doshi Dipal | CEO | F | Common Stock | 17566 | $11.68 | 424,387.0000 | 39,003,169 | 3.97% | 0.05% |
| March 1, 2025 | Entrada Therapeutics, Inc. | $TRDA | Doshi Dipal | CEO | A | Stock Option (Right to Buy) | 173400 | $0.00 | 173,400.0000 | 39,003,169 | 9999.99% | 0.44% |
| Feb. 7, 2025 | Azenta, Inc. | $AZTA | Doshi Dipal | Not found | A | Common | 4040 | $52.32 | 4,040.0000 | 45,626,000 | 9999.99% | 0.01% |
| Sept. 3, 2024 | Entrada Therapeutics, Inc. | $TRDA | Doshi Dipal | CEO | F | Common Stock | 2328 | $15.76 | 332,147.0000 | 33,050,319 | 0.70% | 0.01% |
| Sept. 3, 2024 | Entrada Therapeutics, Inc. | $TRDA | Doshi Dipal | CEO | F | Common Stock | 752 | $16.93 | 331,395.0000 | 33,050,319 | 0.23% | 0.00% |
| Sept. 3, 2024 | Entrada Therapeutics, Inc. | $TRDA | Doshi Dipal | CEO | F | Common Stock | 72 | $17.70 | 331,323.0000 | 33,050,319 | 0.02% | 0.00% |
| Sept. 4, 2024 | Entrada Therapeutics, Inc. | $TRDA | Doshi Dipal | CEO | F | Common Stock | 4744 | $15.42 | 326,579.0000 | 33,050,319 | 1.43% | 0.01% |
| Sept. 5, 2024 | Entrada Therapeutics, Inc. | $TRDA | Doshi Dipal | CEO | F | Common Stock | 826 | $15.13 | 325,753.0000 | 33,050,319 | 0.25% | 0.00% |
| July 15, 2024 | Entrada Therapeutics, Inc. | $TRDA | Doshi Dipal | CEO | S | Common Stock | 1600 | $17.81 | 334,475.0000 | 33,050,319 | 0.48% | 0.00% |
| July 12, 2024 | Entrada Therapeutics, Inc. | $TRDA | Doshi Dipal | CEO | S | Common Stock | 300 | $18.00 | 336,075.0000 | 33,050,319 | 0.09% | 0.00% |
| June 13, 2024 | Entrada Therapeutics, Inc. | $TRDA | Doshi Dipal | CEO | S | Common Stock | 1000 | $16.17 | 336,375.0000 | 33,050,319 | 0.30% | 0.00% |
| May 17, 2024 | Entrada Therapeutics, Inc. | $TRDA | Doshi Dipal | CEO | S | Common Stock | 1200 | $15.11 | 337,375.0000 | 33,050,319 | 0.35% | 0.00% |
| May 16, 2024 | Entrada Therapeutics, Inc. | $TRDA | Doshi Dipal | CEO | S | Common Stock | 1800 | $15.00 | 338,575.0000 | 33,050,319 | 0.53% | 0.01% |
| March 1, 2024 | Entrada Therapeutics, Inc. | $TRDA | Doshi Dipal | CEO | A | Common Stock | 104700 | $0.00 | 347,979.0000 | 33,050,319 | 43.04% | 0.32% |
| March 5, 2024 | Entrada Therapeutics, Inc. | $TRDA | Doshi Dipal | CEO | F | Common Stock | 5049 | $12.28 | 340,375.0000 | 33,050,319 | 1.46% | 0.02% |
| March 4, 2024 | Entrada Therapeutics, Inc. | $TRDA | Doshi Dipal | CEO | F | Common Stock | 1391 | $13.37 | 345,424.0000 | 33,050,319 | 0.40% | 0.00% |
| March 4, 2024 | Entrada Therapeutics, Inc. | $TRDA | Doshi Dipal | CEO | F | Common Stock | 1164 | $12.42 | 346,815.0000 | 33,050,319 | 0.33% | 0.00% |
| March 1, 2024 | Entrada Therapeutics, Inc. | $TRDA | Doshi Dipal | CEO | A | Stock Option (Right to Buy) | 158500 | $0.00 | 158,500.0000 | 33,050,319 | 9999.99% | 0.48% |
| Feb. 15, 2024 | Entrada Therapeutics, Inc. | $TRDA | Doshi Dipal | CEO | S | Common Stock | 1000 | $15.00 | 243,279.0000 | 33,050,319 | 0.41% | 0.00% |
| Jan. 16, 2024 | Entrada Therapeutics, Inc. | $TRDA | Doshi Dipal | CEO | S | Common Stock | 1000 | $15.99 | 244,279.0000 | 33,050,319 | 0.41% | 0.00% |